Ankylosing Spondylitis Biomarker Analysis via Transcriptomics and Mendelian Randomization

Research data identifies novel biomarkers for Ankylosing Spondylitis through transcriptomic profiling and Mendelian randomization analysis. The study demonstrates marked downregulation of RORA and FBXO31 and increased expression of MSRB3 in patient blood samples. Findings highlight causal contributions to disease risk and suggest potential therapeutic agents like indirubin and pentoxifylline.

Use Cases

• Validate the causal association between ISR-related genes like RORA, FBXO31, and MSRB3 and AS susceptibility using Mendelian randomization methods.
• Analyze correlations between identified biomarker expression levels and immune cell infiltration, particularly Th1 cells and keratinocytes.
• Cross-reference transcriptomic profiling results from peripheral blood with drug prediction analyses to identify candidate therapeutic agents.
• Investigate the involvement of olfactory transduction pathways in AS pathogenesis through functional enrichment of the biomarker set.

Strengths

• Includes validation via RT–qPCR on clinically collected blood samples.
• Applies multiple analytical methods: transcriptomic profiling, Mendelian randomization, functional enrichment, and drug prediction.
• Released under a permissive CC BY 4.0 license.

Limitations

• Dataset scope is limited to a 12.1 KB document containing analysis results, not the underlying raw transcriptomic data.
• Sample size for clinical validation and specific row/column counts for analytical datasets are not provided.
• Geographic and demographic details of the patient cohort are unknown.

Provenance

Source

Shuai Wang via figshare.

Collection Method

Transcriptomic profiling of peripheral blood from AS patients, combined with Mendelian randomization and subsequent functional analyses.

Time Range

null

Freshness

Last updated March 2026.

Geography

null